Neurophet

Neurophet ROCE

The Return on Capital Employed (ROCE) of Neurophet (380550.KQ) as of Oct 15, 2026 is -85.08 %. In the previous year, Return on Capital Employed (ROCE) was 23.65 % — a change of -459.78% (lower).

ROCE

-85.08 %

YoY

-459.78%

Last updated:

In 2025, Neurophet's return on capital employed (ROCE) was -85.08 %, a -459.78% increase from the 23.65 % ROCE in the previous year.

The Neurophet ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2022
21.55 KRW
Jan 1, 2023
-14.89 KRW
Jan 1, 2024
23.65 KRW
Jan 1, 2025
-85.08 KRW
The Neurophet ROCE history
YEARROCEYoY
-85.08 %-459.78%
23.65 %-258.77%
-14.89 %-169.12%
21.55 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurophet Stock analysis

What does Neurophet do? Neurophet Inc is a South Korean company operating in the Health Care sector, headquartered in Seoul. The company has 135 employees and is listed on the Korean stock exchange with the ticker 380550.KQ and ISIN KR7380550004. Neurophet Inc went public on July 25, 2025, marking its initial public offering. The company focuses on the research, development, and sales of brain imaging analysis software, including PET image quantitative analysis software called 'Neurophet SCALE PET' and neurodegenerative brain disease diagnosis support software named 'Neurophet AQUA'. Additionally, Neurophet Inc develops and sells therapeutic medical devices and provides medical artificial intelligence solutions. The company's website is https://www.neurophet.com/. Neurophet Inc operates within the Health Care Technology industry, specializing in software and AI-driven tools for medical imaging and diagnostics. The company's products are designed to support healthcare professionals in analyzing brain imaging data and diagnosing neurological conditions. As a technology-focused health care provider, Neurophet Inc aims to enhance diagnostic accuracy and efficiency through its software solutions. The company's operations are based in Seoul, South Korea, and it is engaged in both the development and commercialization of its medical technology products. Neurophet Inc's business model centers on creating innovative software tools that address specific challenges in neurology and brain imaging analysis. Neurophet is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling Neurophet's Return on Capital Employed (ROCE)

Neurophet's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Neurophet's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Neurophet's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Neurophet’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Neurophet stock

Return on Capital Employed (ROCE) of Neurophet is -85.08 % in 2025.

Return on Capital Employed (ROCE) of Neurophet changed from 23.65 % to -85.08 %, representing a -459.78% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) Neurophet since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s Neurophet with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Neurophet

All Key Metrics — Neurophet